NICE recommend Migalastat for the treatment of Fabry disease for individuals over the age of 16 years with an amenable mutation.
The National Institute for Health and Care Excellence (NICE) has today released their final decision (FED) to recommend Migalastat for the treatment of Fabry in people over 16 years of age with an amenable mutation. This is on the proviso that the discount agreed in the patient access scheme is applied and that only those who would be offered Enzyme Replacement Therapy (ERT) be considered.
Consultees have until 5pm on the 18 January 2017 to notify NICE of any factual errors or to lodge an appeal against it.
NHS England now has 3 months to ensure that Migalastat is available for use in line with NICE’s recommendations.
Read the full reports here.